Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS ...

A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and ...

A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline. Among those surveyed, 83 percent ...